© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
May 02, 2022
There was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.
September 16, 2021
A phase 1/2a clinical trial assessing VOR33 is currently enrolling.